Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute

Immunology

About the Immunology Program

AHCMCC2 - Image - 180x272 - Yoji ShimizuProgram Leader: Yoji Shimizu, Ph.D.

The Immunology Program has 21 members from departments in the University of Minnesota Medical School, the College of Veterinary Medicine, and the College of Science and Engineering.

The scientific goal of the Immunology Program is to define the basic mechanisms that control adaptive immunity in order to develop immunotherapies that overcome the significant barriers associated with generating a durable immune response against tumor-associated antigens.

Research themes:

  • Mechanisms of lymphocyte tolerance
  • Lymphocyte activation and signal transduction
  • Mechanisms of lymphocyte development
  • Tumor immunology and immunotherapy
Program Meetings

The Immunology Program meetings are held concurrent with meetings of the Center for Immunology.

    Research Program Members
  • AHCMCC - Image - 70x80 - Paul Bohjanen

    bohja001@umn.edu
    612-625-7679  

    Paul Bohjanen, M.D., Ph.D.
    Role of mRNA decay in regulating T cell activation and function

    AHCMCC - Image - 70x80 - Michael Farrar

    farra005@umn.edu
    612-625-0401

    Michael Farrar, Ph.D.
    How cytokines and cytokine-dependent signal transduction pathways control regulatory T cell development and B cell leukemia

    AHCMCC2 - Image - 70x80 - Brian Fife

    bfife@umn.edu
    612-624-2417

    Brian Fife, Ph.D.
    The PD-1 negative regulatory pathway in T cells and its role in controlling autoimmunity and preventing transplant rejection

    AHCMCC2 - Image - 70x80 - Thomas Griffith

    tgriffit@umn.edu
    624-8269

    Thomas Griffith, Ph.D.
    The immunotherapeutic potential of TRAIL in preclinical models of advanced renal cell carcinoma and breast cancer

    AHCMCC - Image - 70x80 - Kris Hogquist

    hogqu001@umn.edu
    612-625-1616

    Kris Hogquist, Ph.D.
    Molecular mechanisms of T cell development in the thymus; analysis of transgenic and gene-deficient mice, gene expression profiling, and RNAi "knock-down" analysis;immune response to the Epstein Barr Virus - a chronic viral infection associated with cancer and autoimmunity in humans

    AHCMCC - Image - 70x80 - Stephen Jameson

    james024@umn.edu
    612-625-1496  

    Stephen Jameson, Ph.D.
    Mechanisms that regulate the development and maintenance of T cells in the body; T cell homeostasis in response to lymphopenia which offers an opportunity to enhance the function of residual T cells in lymphodepleted individuals, including cancer patients receiving radio- or chemotherapy

    AHCMCC - Image - 70x80 - Marc Jenkins

    jenki002@umn.edu
    612-626-2715  

     Marc Jenkins, Ph.D.
    Investigation of CD4+ helper T and B cell activation in vivo by directly tracking antigen-specific cells, with the goal of achieving a basic understanding of lymphocyte signal transduction, proliferation, and differentiation so that these processes can be manipulated to improve vaccines and prevent autoimmunity

    AHCMCC2 - Image - 70x80 - Dan Kaplan

    dankaplan@umn.edu
    612-626-9400  

    Daniel Kaplan, M.D., Ph.D.
    Function of dendritic cells in initiating T cell-specific immune responses

    AHCMCC - Image - 70x80 - Walter Low

    lowwalt@umn.edu
    612-626-9200

    Walter Low, Ph.D.
    Development of immunotherapeutic approaches for the treatment of brain tumors

    AHCMCC - Image - 70x80 - Matthew Mescher

    mesch001@umn.edu
    612-625-2199  

    Matthew Mescher, Ph.D.
    Investigation of the basic mechanisms involved in CD8 activation and tolerance induction and their application to murine models of tumor immunotherapy. These basic research findings have been translated to the clinic with clinical testing of large multivalent immunogen therapy.

    AHCMCC - Image - 70x80 - Jeffrey Miller

    mille011@umn.edu
    612-625-7409  

    Jeffrey Miller, M.D.
    How undifferentiated stem cells develop into functioning NK cell lymphocytes and the manipulation of NK cells to treat or prevent cancer relapse; targeted immunotherapy to treat human cancer

    AHCMCC2 - Image - 70x60 - Christopher Moertel

    moert001@umn.edu
    612-625-3229

    Christopher Moertel, M.D.
    Clinical interests include pediatriac neuro-oncology; rare pediatric tumors; neurofibromatosis-associated neoplasia; and the therapy of children with brain and spinal cord tumors.

    AHCMCC - Image - 70x80 - Daniel Mueller

    muell002@umn.edu
    612-625-1155
     

    Daniel Mueller, M.D.
    Biological and biochemical nature of immune self-tolerance and application to the treatment of autoimmune disease, allograft rejection, and immunotherapy of cancer

    AHCMCC - Image - 70x80 - Christopher Pennell

    penne001@umn.edu
    612-625-7138

    Christopher Pennell, Ph.D.
    Enhancing the efficacy of DNA-based vaccines for cancer therapy

    AHCMCC - Image - 70x80 - Erik Peterson

    peter899@umn.edu
    612-625-1155  

    Erik Peterson, M.D.
    The role of adaptor proteins in T cell development, regulation of T cell-dependent autoimmunity, and immune cell transduction

    AHCMCC - Image - 70x80 - Elizabeth Pluhar

    pluha006@umn.edu
    612-625-1162  

    Liz Pluhar, D.V.M., Ph.D.
    Gene therapy for glioblastoma multiforme (GBM) and developing dogs with spontaneous glioma as an exceptional large animal model for human GBM and mengingiomas

    AHCMCC2 - Image - 70x80 - Daniel Saltzman

    saltz002@umn.edu
    612-626-4214

    Daniel Saltzman, M.D., Ph.D.
    Development of an attenuated strain of Salmonella typhimurium as an anti-cancer therapy capable of local delivery of immunostimulatory cytokines

    AHCMCC - Image - 70x80 - Yoji Shimizu

    shimi002@umn.edu
    612-626-6849

    Yoji Shimizu, Ph.D.
    Intracellular signal transduction events that regulate adhesion interactions critical for effective antigen-specific immune responses and cell trafficking

    AHCMCC2 - Image - 70x80 - Vaiva Vezys

    vvezys@umn.edu
    612-625-4650

    Vaiva Vezys, Ph.D.
    Investigation of how T cell tolerance to self-antigens, tumor antigens, and proteins from chronic infections is induced and maintained; development of methods for reversing established tolerance to these types of proteins and their translation to the clinic

    AHCMCC2 - Image - 70x80 - Chun Wang

    wangx504@umn.edu
    612-626-3990

    Chun Wang, Ph.D.
    Development of novel polymer-based biomaterials for the delivery of cancer chemo- and immunotherapeutics

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on January 10, 2014